Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 11, 2013, Pages 832-836

  Lahu, Gezim ^a   Facius, Axel ^a  

^a Takeda Pharmaceuticals International GmbH   (Switzerland)

Author keywords

Adverse events; COPD; Modeling; Pharmacokinetics; Roflumilast

Indexed keywords

DRUG METABOLITE; ROFLUMILAST;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; HEADACHE; HUMAN; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PREDICTION; SIMULATION;

AMINOPYRIDINES; BENZAMIDES; CYCLOPROPANES; HUMANS; LOGISTIC MODELS; MODELS, BIOLOGICAL; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84887032283     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201906     Document Type: Article

References (12)

1. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011; 163: 53-67. CrossRef PubMed
2. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009; 374: 685-694. CrossRef PubMed
3. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF; M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009; 374: 695-703. CrossRef PubMed
4. Bateman ED, Rabe KF, Calverley PM, Goehring UM, Brose M, Bredenbröker D, Fabbri LM. Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history. Eur Respir J. 2011; 38: 553-560. CrossRef PubMed
5. Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respir Res. 2011; 12: 18. CrossRef PubMed
6. Calverley PMA, Martinez FJ, Fabbri LM, Goehring UM, Rabe KF. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J Chron Obstruct Pulmon Dis. 2012; 7: 375-382. PubMed
7. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbröker D, Bethke TD. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005; 366: 563-571. CrossRef PubMed
8. Lahu G, Hünnemeyer A, Diletti E, Elmlinger M, Ruth P, Zech K, McCracken N, Facius A. Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model. Clin Pharmacokinet. 2010; 49: 589-606. CrossRef PubMed
9. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001; 297: 267-279. PubMed
10. Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H. The preclinical pharmacology of roflumilast - a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010; 23: 235-256. CrossRef PubMed
11. Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A, Ayres JG, Creemers JP, Schultze-Werninghaus G, Brambilla C, Barnes NC; International Study Group. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet. 2001; 358: 265-270. CrossRef PubMed
12. Rennard S, Knobil K, Rabe KF, Morris A, Schachter N, Locantore N, Canonica WG, Zhu Y, Barnhart F. The efficacy and safety of cilomilast in COPD. Drugs. 2008; 68 (Suppl 2): 3-57. CrossRef PubMed